NeuroPace, Inc. (NPCE) Financial Ratios
7 years of historical data (2019–2025) · Healthcare · Medical - Devices
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
33.17
↑+99% vs avg
5yr avg: 16.69
30Y Low1.1·High40.7
ROE
↓
N/A
—
5yr avg: -111.1%
30Y Low-189%·High-49%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
NPCE Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
NeuroPace, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $648M | $505M | $326M | $267M | $37M | $167M | — | — |
| Enterprise Value | $697M | $554M | $386M | $321M | $100M | $198M | — | — |
| P/E Ratio → | -29.23 | — | — | — | — | — | — | — |
| P/S Ratio | 6.48 | 5.05 | 4.08 | 4.07 | 0.81 | 3.71 | — | — |
| P/B Ratio | 33.17 | 26.55 | 40.67 | 12.90 | 1.05 | 2.28 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
NPCE EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 5.54 | 4.83 | 4.90 | 2.19 | 4.38 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
NPCE Profitability
Margins and return-on-capital ratios measuring operating efficiency
NeuroPace, Inc. earns an operating margin of -16.3%. Operating margins have expanded from -41.5% to -16.3% over the past 3 years, signaling improving operational efficiency.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 77.2% | 77.2% | 73.9% | 73.6% | 71.4% | 74.0% | 73.6% | 71.6% |
| Operating Margin | -16.3% | -16.3% | -27.1% | -41.5% | -89.6% | -52.5% | -31.7% | -59.6% |
| Net Profit Margin | — | — | -34.0% | -50.4% | -103.4% | -79.9% | -59.0% | -81.1% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | — | — | -189.4% | -118.9% | -87.0% | -49.1% | — | — |
| ROA | — | — | -26.8% | -29.7% | -38.0% | -38.1% | -63.0% | -142.1% |
| ROIC | -18.0% | -18.0% | -22.7% | -23.6% | -30.3% | — | — | — |
| ROCE | -19.5% | -19.5% | -25.4% | -27.9% | -35.9% | -27.8% | -28.2% | — |
NPCE Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $49M ($71M total debt minus $22M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 3.72 | 3.72 | 9.15 | 3.51 | 2.01 | 0.68 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 2.58 | 7.48 | 2.63 | 1.82 | 0.42 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -2.46 | -3.19 | -5.42 | -3.20 | -1.14 | -2.32 |
NPCE Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
NeuroPace, Inc.'s current ratio of 5.28x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 4.33x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 5.71x to 5.28x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.28 | 5.28 | 5.37 | 5.71 | 8.90 | 14.28 | 5.69 | 0.27 |
| Quick Ratio | 4.33 | 4.33 | 4.48 | 5.02 | 8.02 | 13.44 | 4.97 | 0.16 |
| Cash Ratio | 3.43 | 3.43 | 3.48 | 4.09 | 7.05 | 12.43 | 3.97 | 0.07 |
| Asset Turnover | — | 0.95 | 0.84 | 0.61 | 0.40 | 0.34 | 0.74 | 1.75 |
| Inventory Turnover | 1.35 | 1.35 | 1.56 | 1.54 | 1.34 | 1.50 | 1.57 | 1.33 |
| Days Sales Outstanding | — | 53.59 | 58.70 | 68.70 | 59.99 | 57.28 | 74.49 | 59.40 |
NPCE Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
NeuroPace, Inc. returns 7.6% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 7.6% | 9.8% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 7.6% | 9.8% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $33M | $29M | $26M | $25M | $17M | $11M | $11M |
Peer Comparison
Compare NPCE with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 NPCEYou | $648M | -29.2 | — | — | 77.2% | -16.3% | — | -18.0% | — |
 LIVN | $4B | -15.9 | 15.4 | 22.4 | 67.7% | 14.4% | -19.2% | 11.5% | 2.0 |
 ELMD | $222M | 31.2 | 19.1 | 20.1 | 78.1% | 15.1% | 17.2% | 25.6% | 0.0 |
 MDT | $100B | 21.6 | 14.3 | 19.3 | 65.3% | 17.8% | 9.4% | 6.0% | 3.2 |
 ABT | $151B | 11.4 | 15.8 | 23.8 | 50.8% | 16.3% | 30.9% | 9.9% | 1.5 |
 BSX | $84B | 29.2 | 25.3 | 23.0 | 69.0% | 19.8% | 12.4% | 8.8% | 3.3 |
 NVCR | $2B | -13.8 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 INVA | $2B | 6.9 | 8.1 | 9.9 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 ISRG | $161B | 57.6 | 43.6 | 64.7 | 66.0% | 29.3% | 16.6% | 15.0% | 0.1 |
 TNDM | $1B | -6.1 | — | — | 52.3% | -7.7% | -97.9% | -10.0% | — |
 INSP | $1B | 9.3 | 19.1 | 16.7 | 85.4% | 5.6% | 19.8% | 6.0% | 0.5 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
See NPCE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NPCE Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NPCE vs LIVN
Side-by-side business, growth, and profitability comparison vs LivaNova PLC.
Start ComparisonNPCE — Frequently Asked Questions
Quick answers to the most common questions about buying NPCE stock.
What is NeuroPace, Inc.'s P/E ratio?
NeuroPace, Inc.'s current P/E ratio is -29.2x. This places it at the 50th percentile of its historical range.
Is NPCE stock overvalued?
Based on historical data, NeuroPace, Inc. is trading at a P/E of -29.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are NeuroPace, Inc.'s profit margins?
NeuroPace, Inc. has 77.2% gross margin and -16.3% operating margin.